TRANSFUSION:与安慰剂相比,在严重创伤性出血患者中早期静脉推注 2 克和 4 克氨甲环酸的血栓栓塞事件风险:一项随机、双盲、安慰剂对照、单中心试验的二次分析

2022-09-01 将军的九分裤 MedSci原创

创伤性损伤死亡是全球青年和儿童最常见的死亡原因,比疟疾、肺结核和人类免疫缺陷病毒/获得性免疫缺陷综合征死亡的总和还要常见。

创伤性损伤死亡是全球青年和儿童最常见的死亡原因,比疟疾、肺结核和人类免疫缺陷病毒/获得性免疫缺陷综合征死亡的总和还要常见。目前随机临床试验尚未对严重创伤性损伤患者因氨甲环酸 (TXA) 引起的血栓栓塞 (TE) 风险进行筛查。国外一研究团队进行的TAMPITI 试验提供了一个评估这个问题的机会,研究目标是确定 TXA 剂量是否与血栓栓塞独立相关。

研究是一项前瞻性、单中心、双盲 RCT,于 2016 年 3 月-2017 年 9 月在三级护理中心圣路易斯华盛顿大学 (Wash U) 进行,研究人员使用多变量离散时间 Cox 回归模型来确定与入组后 30 天内血栓栓塞事件风险的关联。使用离散时间 Cox 回归创建事件曲线。

图1:TAMPITI 患者筛查、登记、随机化和分析图。此综合报告试验标准 (CONSORT) 图显示了筛选合格、因不符合研究纳入标准而排除的患者数量、入组和随机分组的患者、每个研究组分析的患者以及每项研究中发生血栓栓塞事件的患者数量团体

图2:非血栓栓塞事件和血栓栓塞事件患者之间可溶性因子动力学的差异。数据显示为中值,误差条代表四分位间距(第 1 至第 3)。使用两样本非配对t检验比较数据。p值如下所示:* p  < .05;** p  < .01; *** p  < .001。PF 1.2,凝血酶原片段 1 和 2;SDC1,syndecan-1

图3:每个干预组血栓栓塞事件的累积概率

结果提示,安慰剂组有 50 名患者,2-g 组有 49 名患者,4-g TXA 组有 50 名患者。在血栓栓塞的校正分析中,2 g 剂量的 TXA 的风险比(HR,95% 置信区间 [CI])为 3.20 (1.12-9.11) (p = .029),而 4 g 剂量的 TXA的 HR (95% CI) 为 5.33 (1.94-14.63) (p = .001)。与安慰剂相比,两种剂量的 TXA 发生血栓栓塞的可能性更高。与血栓栓塞独立相关的其他参数包括从受伤到给予 TXA 的时间、体重指数和输注的总血制品。

总的来说,严重创伤性损伤患者 30 天内发生血栓栓塞的风险随着 TXA 给药而增加,并且呈剂量依赖性。血栓栓塞还与 BMI 增加和 TXA 前输注的血制品总量有关需要进一步的研究来确定是否应根据患者因素(如 BMI)改变 TXA 的剂量和使用时间。虽然不应对严重创伤性损伤和出血的患者停用 TXA,但对于因创伤性出血接受至少 2 g TXA 静脉内剂量的患者,应考虑进行血栓栓塞筛查。

 

原始出处:

Spinella, PCBochicchio, KThomas, KAStaudt, AShea, SMPusateri, AE, et al. The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trialTransfusion202262S1): S139– S150. https://doi.org/10.1111/trf.16962.

评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2022-10-09 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2023-03-30 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2023-02-27 bsmagic9140

    #TRA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2022-11-22 tcm110hq

    #Fusion#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2023-07-29 amyloid

    #对照#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2022-09-03 fusion

    #静脉#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2022-09-02 wleon8895
  10. [GetPortalCommentsPageByObjectIdResponse(id=2025549, encodeId=fe39202554952, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Oct 09 00:04:07 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954056, encodeId=2cd8195405624, content=<a href='/topic/show?id=555a211585a' target=_blank style='color:#2F92EE;'>#严重创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21158, encryptionId=555a211585a, topicName=严重创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Mar 30 11:04:07 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657677, encodeId=5540165e6778c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Feb 27 07:04:07 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795834, encodeId=33101e95834b8, content=<a href='/topic/show?id=b3f81e747da' target=_blank style='color:#2F92EE;'>#Transfusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17747, encryptionId=b3f81e747da, topicName=Transfusion)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Mar 27 16:04:07 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720722, encodeId=51f31e207223c, content=<a href='/topic/show?id=8163e726a0' target=_blank style='color:#2F92EE;'>#Fusion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7726, encryptionId=8163e726a0, topicName=Fusion)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f10932951504, createdName=tcm110hq, createdTime=Tue Nov 22 11:04:07 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775664, encodeId=f4c41e7566495, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jul 29 07:04:07 CST 2023, time=2023-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029193, encodeId=75572029193cf, content=<a href='/topic/show?id=f2c862006ea' target=_blank style='color:#2F92EE;'>#栓塞事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62006, encryptionId=f2c862006ea, topicName=栓塞事件)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Mon Sep 19 16:04:07 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698420, encodeId=d5aa16984207f, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 03 22:04:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304436, encodeId=50b8130443680, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335414, encodeId=f143133541439, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Sep 02 14:04:07 CST 2022, time=2022-09-02, status=1, ipAttribution=)]
    2022-09-02 ms920641618706883

    #创伤#

    0

相关资讯

J Thromb Haemost:噬血细胞性淋巴组织细胞增生症成人出血和血栓栓塞发生率及其对总生存率的影响

在噬血细胞性淋巴组织细胞增生症的成人中,VTE似乎比之前描述的更常见,并且是患者死亡的预测因子,尽管这可能是由于未经调整的混杂因素所致。由于出血率高,VTE的预防和治疗具有挑战性。

Pacing Clin Electrophysiol:全球EMIT研究结果——行起搏器和心脏监测装置植入术后患者应用艾多沙班的血栓栓塞和出血风险

接受起搏器或侵入性心脏监测植入的艾多沙班治疗患者的围手术期并发症风险较低。

JGH:肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物

肝细胞癌(HCC)是肝癌的主要组织学亚型,占原发性肝癌的90%,是全世界癌症相关死亡率的第三大常见原因。

SCI REP:如何评估癌症住院患者的血栓栓塞风险?

低KS可作为住院癌症患者的血栓形成的负面预测因素;未来或可评估已确定住院相关 TEs 低风险的患者避免 TP 的安全性。

J Gastroenterology:炎症性肠病患者动静脉血栓栓塞导致的死亡率和风险因素分析

炎症性肠病 (IBD) 是一种慢性复发性肠道和全身炎症性疾病,有两种主要的表型:溃疡性结肠炎 (UC) 和克罗恩病 (CD)。而血栓栓塞(TE)是一种严重的肠

J INTERN MED:巨细胞动脉炎和/或风湿性多肌痛患者的血栓栓塞风险如何?

GCA、PMR和两种疾病合并的患者发生血栓栓塞事件风险各补相同。研究人员发现可能有助于根据疾病表型预测血栓栓塞事件的风险。

拓展阅读

血栓栓塞的获得性因素

从条件到评论,一文全解,让你快速掌握血栓栓塞的获得性因素。

Nature:90后华人学者革新血栓清除术,助力卒中、心脏病治疗迎来新时代

近年来,血栓相关疾病如中风、心肌梗死、肺栓塞等仍然是全球健康的头号杀手。尽管医疗技术不断进步,但如何快速、彻底、安全地清除血管内血栓,一直是临床急诊和介入治疗的难题。日前,斯坦福大学赵芮可教授团队的一

Lancet neurology:扩大CT血管造影显著提高血栓检出率

在急性缺血性卒中和短暂性脑缺血发作(TIA)的诊断中,心脏和大动脉血栓常常难以被发现。

惊爆!南开大学最新研究:人参皂苷CK精准打击PHD2,颠覆性抑制血栓生成!

文章探究了中药人参提取物皂苷CK如何增强血流动力学循环,缓解血瘀的相关作用机制。

Cancers:血栓栓塞事件的发生与血液恶性肿瘤诊断之间的时间关系

在诊断血液系统恶性肿瘤之前,ATE 的发生率明显高于 VTE,尤其是在有明显心脏病史的患者中。

Am J Obstet Gynecol:在大型全国队列中,早产先兆子痫是血栓栓塞的独立危险因素

早产子痫前期与妊娠期血栓栓塞风险密切相关,而这种关联与足月子痫前期不同,强调了早产子痫前期患者在妊娠期间需要更严密的监测和预防措施。

2020 SMFM咨询系列#51:剖腹产术中血栓栓塞的预防

母胎医学会(SMFM,Society for Maternal-Fetal Medicine) · 2020-08-22

左心耳干预预防心房颤动患者血栓栓塞事件:目前的认识和建议-2019

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2019-10-30

2016 ASRM指南:联合应用激素避孕与静脉血栓栓塞风险

美国生殖医学会(ASRM,American Society for Reproductive Medicine) · 2016-10-25